290 likes | 476 Views
Breast Cancer Highlights: San Antonio, 2012. N9831/B31: DFS and OS (8-Year Follow-up). B31/N9831:Cumulative Incidence of Distant Recurrence as a First Event. Duration of Adjuvant Trastuzumab (8-Year Follow-up): OS -- 2 y vs 1 y. ATLAS: 10 vs 5 Years of Tamoxifen.
E N D
B31/N9831:Cumulative Incidence of Distant Recurrence as a First Event
Duration of Adjuvant Trastuzumab (8-Year Follow-up): OS -- 2 y vs 1 y
BEATRICE: Chemotherapy +/– Bevacizumab in Triple-Negative Breast Cancer -- DFS
Sentinel Lymph Node Mapping Before/After Neoadjuvant Chemotherapy
CALOR Trial: Chemotherapy for Local/Regional Recurrence of Breast Cancer